Nemes Rush Group’s Edwards Lifesciences EW Stock Holding History

Nemes Rush Group’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$20.4K	Hold	236	–	–	﹤0.01%	473
2026 Q2	$21.3K	Buy	236 +140	+146%	+$11.7K	﹤0.01%	481
2026 Q1	$7.69K	Sell	96 -9	-9%	-$742	﹤0.01%	577
2025 Q4	$8.95K	Buy	105 +9	+9%	+$739	﹤0.01%	562
2025 Q3	$7.47K	Sell	96 -6	-6%	-$469	﹤0.01%	515
2025 Q2	$7.98K	Buy	102 +6	+6%	+$447	﹤0.01%	499
2025 Q1	$6.96K	Sell	96 -179	-65%	-$12.8K	﹤0.01%	504
2024 Q4	$20.4K	Sell	275 -8,924	-97%	-$625K	﹤0.01%	393
2024 Q3	$879K	Sell	9,199 -1,770	-16%	-$129K	0.13%	91
2024 Q2	$1.01M	Buy	10,969 +1,651	+18%	+$146K	0.14%	85
2024 Q1	$890K	Sell	9,318 -45,919	-83%	-$3.86M	0.13%	92
2023 Q4	$4.21M	Buy	55,237 +2,995	+6%	+$208K	0.68%	44
2023 Q3	$3.62M	Buy	52,242 +4,301	+9%	+$346K	0.66%	45
2023 Q2	$4.52M	Buy	+47,941	New	+$4.17M	0.8%	42

Other funds holding EW

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Mirova US Boston, Massachusetts $9.15B AUM 21.91% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $64.1B AUM 28.9% 1-Year Est. Return

Nemes Rush Group's EW Position: Q3 2026 in Review

Nemes Rush Group held its Edwards Lifesciences (EW) position steady in Q3 2026 at 236 shares worth $20.4K. The position accounts for ﹤0.01% of the portfolio, ranked #473.

Nemes Rush Group first reported a position in EW in Q2 2023 and has held it in 14 quarters since. The position peaked at $4.52M in Q2 2023. 719 funds tracked by Wall St. Rank hold EW as of Q3 2026.

Nemes Rush Group held 236 shares of Edwards Lifesciences worth $20.4K as of Q3 2026.
Nemes Rush Group left its Edwards Lifesciences share count unchanged in Q3 2026.
Edwards Lifesciences made up ﹤0.01% of Nemes Rush Group's portfolio in Q3 2026, its #473 holding.
Nemes Rush Group first reported a position in Edwards Lifesciences in Q2 2023 and has held it in 14 quarters since.
Nemes Rush Group's Edwards Lifesciences position peaked at $4.52M in Q2 2023.
719 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Nemes Rush Group's 13F filing for Q3 2026, filed 4 Nov 2026.